Relapsed Ovarian Cancer- Alternative?

Hello David; My wife has ovarian cancer. After a series of conventional chemotherapy treatments, we are considering antineoplaston therapy at the Burzynski Research Institute (BRI).

A little backgroud. My wife is 52 years old and in good health otherwise. She has had a successful operation to remove her ovaries. Her CA125 started in the 3,000 range, after the first round of Carboplatin/Taxol got down to 41. Then popped up, so we went to a new chemo regimen, Gemzar/Avastin.

Her CA125 dropped to 300 then went up. Then we were on Taxotere/Avastin for last couple of months, her CA125 dropped, to 3,000 but CT Scan didn’t show progress.

The recommendation was to go to a new drug. I have to say that my wife is getting fatigued by all the chemotherapy.

Now we have an appointment qt Burzynski Clinic this Tuesday. Do you recommend that?

We look forward to get your reply. Sam

Hi Sam,

The best way I know to answer your question “We are looking to go to Burzynski Clinic. Do you recommend that?” is to outline my thinking, my logic.

Your wife’s ovarian cancer situation, as far as I can see from your responses is:

1) Ovarian cancer diagnosis. Ovaries surgically removed to debulk the cancer as completely as possible.

2) Chemotherapy regimens completed thus far-

carboplatin/taxol-partial remission, relapse
gemzar/avastin- partial remission, relapse
taxotere/avastin- possible remission, possibly unresponsive

3) Patient age is 52-average age of ovarian cancer newly diagnosed patient is 63. Length of life becomes a higher priority for the young patient.

4) While length of life is a priority, the toxicity of the previous therapies is taking a toll on the patient. While there may be relapsed/refractory therapies for ovarian cancer patients, I think conventional therapy options are few.

——————————————————

Considerations for Antineoplaston Therapy (ANP) for ovarian cancer.

Though my cancer, multiple myeloma, is very different from ovarian cancer, to some degree I am a “proof of concept.” Because I am only one example, I am linking case results below as well as a Pubmed study.
Though I don’t know if ANP is non-toxic, technically speaking, I can say that ANP therapy is a cakewalk compared to my conventional therapies.
I would not recommend ANP for the newly diagnosed ovarian cancer patient. I believe in your case Sal, the risk/reward equation has changed from that of the newly diagnosed ovarian cancer patient.
Last but not least, its important to emphasize that your health insurance will probably NOT cover ANP therapy.
I will add text info for ANP and the top 20 cancers below.

If I read the ovarian cancer treatment data below correctly, ovarian cancer realized an “objective response rate” of over 50%.

To Learn more about Ovarian Cancer- click now

As you can see Sal, the answer to your question is not a simple yes or no. Let me know if you have any questions.

Hang in there,

David Emerson

Cancer Survivor
Cancer Coach
Director PeopleBeatingCancer

Personalized cancer treatment for ovarian cancer.

“Recently there have been numerous advances in understanding the genetic basis of cancer which have resulted in more appropriate treatments. In this paper we describe the experience of the Burzynski Clinic, involved in treatment of numerous patients based on personalized approach using novel combinations for difficult-to-treat malignancies, with gynecological cancers. This retrospective study was conducted by extracting data from Burzynski Clinic’s medical records and comprehensive review. Among the advanced refractory ovarian cancers cases (N=33), an objective response (OR) was found in 42.4%. We anticipate that with improved technology and novel therapeutics this rate will increase and adverse events will be reduced.”

PERSONALIZED TREATMENT AT BURZYNSKI CLINIC

Comparison of Responses in 20 selected most common cancers (as of September 21, 2015)

Diagnosis	No. of patients	OR (%)	SD (%)	PD (%)
Non-Hodgkin’s Lymphoma	131	64	26	10
Breast Cancer	433	62	23	15
Carcinoma of unknown primary	42	57	36	7
Prostate Cancer	322	53	38	9
Ovarian Cancer	99	51	29	20
Head and Neck Cancer	87	51	29	20
Colon Cancer	229	51	28	21
Hodgkin’s Disease	16	50	38	12
Kidney Cancer	41	49	34	17
Malignant melanoma	63	49	21	30
Lung Cancer	179	46	33	21
Urinary Bladder and Urothelial Cancer	39	45	32	23
Esophageal and Stomach Cancer	55	44	29	27
Liver Cancer	20	40	25	35
Uterine, Cervix, Vulvar, Endometrium	51	39	31	30
Brain Tumor	189	37	39	24
Multiple Myeloma	21	36	43
Biliary Tract Tumor	20	30	40	30
Pancreatic Cancer	55	24	51	25
Mesothelioma	17	24	41	35

Data based on medical records of 2,280 evaluable patients

DEFINITIONS:

OR: Objective Response – includes CR and PR.

CR: Complete Response. Complete disappearance of all signs of cancer in response to treatment of 4 weeks or longer.

PR: Partial Response. More than 50% decrease in the size of the tumors in response to treatment of 4 weeks or longer.

SD: Stable Disease. No decrease or increase in the size of the tumors, but no progression, in response to treatment of 12 weeks or longer.

PD: Progressive Disease. More then 50% increase in size of the tumors (the sum of cross-sectional area of the tumors), in response to treatment of 4 weeks or longer.

Evaluable Patients. Patients who remained on treatment long enough to enable an objective evaluation of the response

Diagnosed with Cancer? Your two greatest challenges are understanding cancer and understanding possible side effects from chemo and radiation. Knowledge is Power!

Relapsed Ovarian Cancer- Alternative?

Recommended Reading:

Personalized cancer treatment for ovarian cancer.

Leave a Comment:

Popular posts

Multiple Myeloma Diet

Multiple Myeloma Survivor- A Different kind of Second Opinion-

C-B-D Enhances Velcade (BORT)

Are Endometrial Polyps Overtreated?